{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:06:30Z","timestamp":1793106390083,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The preparation of the manuscript was funded by Eli Lilly and Company."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-03003-8","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:59:01Z","timestamp":1729004341000},"page":"4446-4462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-054X","authenticated-orcid":false,"given":"Axel","family":"Dignass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-0260","authenticated-orcid":false,"given":"Susanne","family":"Hartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Dunnewind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Halfpenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Arc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Hoque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"3003_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501\u201323. https:\/\/doi.org\/10.1038\/ajg.2009.727. (quiz 524).","journal-title":"Am J Gastroenterol"},{"key":"3003_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ajg.2011.386","volume":"107","author":"A Bitton","year":"2012","unstructured":"Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179\u201394. https:\/\/doi.org\/10.1038\/ajg.2011.386. (author reply 195).","journal-title":"Am J Gastroenterol"},{"key":"3003_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"key":"3003_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040622317742095","volume":"9","author":"PS Dulai","year":"2018","unstructured":"Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65\u201372. https:\/\/doi.org\/10.1177\/2040622317742095.","journal-title":"Ther Adv Chronic Dis"},{"key":"3003_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032.","journal-title":"Gastroenterology"},{"key":"3003_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85\u201395. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.048. (quiz e14\u20135).","journal-title":"Gastroenterology"},{"key":"3003_CR7","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med. 2005;353:2462\u201376. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Eng J Med"},{"key":"3003_CR8","doi-asserted-by":"publisher","first-page":"175628482110599","DOI":"10.1177\/17562848211059954","volume":"14","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, Sandborn WJ, Panaccione R, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021;14:17562848211059954. https:\/\/doi.org\/10.1177\/17562848211059954.","journal-title":"Therap Adv Gastroenterol"},{"key":"3003_CR9","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm11092302","volume":"11","author":"F Ferretti","year":"2022","unstructured":"Ferretti F, Cannatelli R, Monico MC, et al. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J Clin Med. 2022;11:2302. https:\/\/doi.org\/10.3390\/jcm11092302.","journal-title":"J Clin Med"},{"key":"3003_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1905725.","journal-title":"N Engl J Med"},{"key":"3003_CR11","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"3003_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMc1707500","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Eng J Med. 2017;376:1723\u201336. https:\/\/doi.org\/10.1056\/NEJMc1707500.","journal-title":"N Eng J Med"},{"key":"3003_CR13","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase\u00a02b\/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00666-8.","journal-title":"Lancet"},{"key":"3003_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1112168.","journal-title":"N Engl J Med"},{"key":"3003_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase\u00a03, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00581-5.","journal-title":"Lancet"},{"key":"3003_CR16","unstructured":"Mirikizumab: European Medicines Agency Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf. Accessed Nov 2023."},{"key":"3003_CR17","unstructured":"Mirikizumab: United States Prescribing Information. https:\/\/pi.lilly.com\/us\/omvoh-uspi.pdf. Accessed Nov 2023."},{"key":"3003_CR18","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med"},{"key":"3003_CR19","unstructured":"Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement. URL: https:\/\/www.prisma-statement.org\/prisma-2020-statement."},{"key":"3003_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3003_CR21","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions, version 6.3 (updated February 2022). Cochrane 2022. www.training.cochrane.org\/handbook. Accessed May\u00a02023."},{"key":"3003_CR22","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews. CRD\u2019s guidance for undertaking reviews in health care. 2009. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed May\u00a02023."},{"key":"3003_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10620-007-9954-6","volume":"53","author":"S Garud","year":"2008","unstructured":"Garud S, Brown A, Cheifetz A, et al. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci. 2008;53:875\u201391. https:\/\/doi.org\/10.1007\/s10620-007-9954-6.","journal-title":"Dig Dis Sci"},{"key":"3003_CR24","doi-asserted-by":"publisher","first-page":"Cd011572","DOI":"10.1002\/14651858.CD011572.pub2","volume":"9","author":"V Jairath","year":"2017","unstructured":"Jairath V, Zou GY, Parker CE, et al. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017;9:Cd011572. https:\/\/doi.org\/10.1002\/14651858.CD011572.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"3003_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/ecco-jcc\/jjab135","volume":"16","author":"R Sedano","year":"2022","unstructured":"Sedano R, Hogan M, Nguyen TM, et al. Systematic review and meta-analysis: clinical, endoscopic, histological and safety placebo rates in induction and maintenance trials of ulcerative colitis. J Crohn Colitis. 2022;16:224\u201343. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab135.","journal-title":"J Crohn Colitis"},{"key":"3003_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrgastro.2015.117","volume":"12","author":"S Elsenbruch","year":"2015","unstructured":"Elsenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2015;12:472\u201385. https:\/\/doi.org\/10.1038\/nrgastro.2015.117.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3003_CR27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/ibd\/izy365","volume":"25","author":"FS Macaluso","year":"2019","unstructured":"Macaluso FS, Maida M, Ventimiglia M, et al. Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small molecule drugs in ulcerative colitis: a meta-analysis. Inflamm Bowel Dis. 2019;25:987\u201397. https:\/\/doi.org\/10.1093\/ibd\/izy365.","journal-title":"Inflamm Bowel Dis"},{"key":"3003_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"3003_CR29","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. NICE Decision Support Unit Technical Support Documents. National Institute for Health and Care Excellence (NICE); 2016."},{"key":"3003_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JPA Ioannidis","year":"2004","unstructured":"Ioannidis JPA, Evans SJW, G\u00f8tzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781\u20138. https:\/\/doi.org\/10.7326\/0003-4819-141-10-200411160-00009.","journal-title":"Ann Intern Med"},{"key":"3003_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073725","volume":"381","author":"DR Junqueira","year":"2023","unstructured":"Junqueira DR, Zorzela L, Golder S, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023;381:e073725. https:\/\/doi.org\/10.1136\/bmj-2022-073725.","journal-title":"BMJ"},{"key":"3003_CR32","unstructured":"National Institute for Health and Care Excellence 2015. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342). https:\/\/www.nice.org.uk\/guidance\/ta342\/resources\/vedolizumab-for-treating-moderately-to-severely-active-ulcerative-colitis-pdf-82602604482757. Accessed Oct 2023."},{"key":"3003_CR33","unstructured":"National Institute for Health and Care Excellence 2015. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329). https:\/\/www.nice.org.uk\/guidance\/ta329\/resources\/infliximab-adalimumab-and-golimumab-for-treating-moderately-to-severely-active-ulcerative-colitis-after-the-failure-of-conventional-therapy-pdf-82602495307717. Accessed Oct 2023."},{"key":"3003_CR34","unstructured":"National Institute for Health and Care Excellence 2018. Tofacitinib for moderately to severely active ulcerative colitis (TA547). https:\/\/www.nice.org.uk\/guidance\/ta547\/resources\/tofacitinib-for-moderately-to-severely-active-ulcerative-colitis-pdf-82606966445509. Accessed Oct 2023."},{"key":"3003_CR35","unstructured":"National Institute for Health and Care Excellence 2022. Ozanimod for treating moderately to severely active ulcerative colitis (TA828). https:\/\/www.nice.org.uk\/guidance\/ta828\/resources\/ozanimod-for-treating-moderately-to-severely-active-ulcerative-colitis-pdf-82613377539781. Accessed Oct 2023."},{"key":"3003_CR36","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: Heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment. NICE Decision Support Unit Technical Support Documents. National Institute for Health and Care Excellence (NICE); 2012."},{"key":"3003_CR37","doi-asserted-by":"publisher","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU TECHNICAL SUPPORT DOCUMENT Evidence Synthesis for Decision Making 3: Heterogeneity\u2014subgroups, meta-regression, bias, and bias-adjustment. NICE Decision Support Unit Technical Support Documents. National Institute for Health and Care Excellence (NICE); 2012. MDM. 2013; 33(5):618\u2013640. https:\/\/doi.org\/10.1177\/0272989X13485157.","DOI":"10.1177\/0272989X13485157"},{"key":"3003_CR38","unstructured":"Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 4: Inconsistency in networks of evidence based on randomised controlled trials. NICE Decision Support Unit Technical Support Documents. National Institute for Health and Care Excellence (NICE); 2014."},{"key":"3003_CR39","unstructured":"Dias S, Welton NJ, Sutton A, et al. NICE DSU Technical Support Document 5: Evidence Synthesis in the Baseline Natural History Model. NICE Decision Support Unit Technical Support Documents. National Institute for Health and Care Excellence (NICE); 2012."},{"key":"3003_CR40","doi-asserted-by":"publisher","unstructured":"Phillippo DM. Multinma: Bayesian network meta-analysis of individual and aggregate data. 2023. https:\/\/doi.org\/10.5281\/zenodo.3904454.","DOI":"10.5281\/zenodo.3904454"},{"issue":"5","key":"3003_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/crocol\/otad009","volume":"360","author":"R Panaccione","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using bayesian network meta-analysis. Crohns Colitis. 2023;360(5):1\u201317. https:\/\/doi.org\/10.1093\/crocol\/otad009.","journal-title":"Crohns Colitis"},{"key":"3003_CR42","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11096-022-01509-1","volume":"45","author":"X Lu","year":"2023","unstructured":"Lu X, Jarrett J, Sadler S, et al. Comparative efficacy of advanced treatments in biologic-na\u00efve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. Int J Clin Pharm. 2023;45:330\u201341. https:\/\/doi.org\/10.1007\/s11096-022-01509-1.","journal-title":"Int J Clin Pharm"},{"key":"3003_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/17474124.2021.1880319","volume":"15","author":"V Jairath","year":"2021","unstructured":"Jairath V, Chan K, Lasch K, et al. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15:711\u201322. https:\/\/doi.org\/10.1080\/17474124.2021.1880319.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3003_CR44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/03007995.2020.1716701","volume":"36","author":"M Welty","year":"2020","unstructured":"Welty M, Mesana L, Padhiar A, et al. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin. 2020;36:595\u2013606. https:\/\/doi.org\/10.1080\/03007995.2020.1716701.","journal-title":"Curr Med Res Opin"},{"key":"3003_CR45","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","volume":"45","author":"A Cholapranee","year":"2017","unstructured":"Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291\u2013302. https:\/\/doi.org\/10.1111\/apt.14030.","journal-title":"Aliment Pharmacol Ther"},{"key":"3003_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000302","volume":"6","author":"C Lohan","year":"2019","unstructured":"Lohan C, Diamantopoulos A, LeReun C, et al. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol. 2019;6:e000302. https:\/\/doi.org\/10.1136\/bmjgast-2019-000302.","journal-title":"BMJ Open Gastroenterol"},{"key":"3003_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20390","volume":"20","author":"R Archer","year":"2016","unstructured":"Archer R, Tappenden P, Ren S, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess. 2016;20:1\u2013326. https:\/\/doi.org\/10.3310\/hta20390.","journal-title":"Health Technol Assess"},{"key":"3003_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165435","volume":"11","author":"AD Vickers","year":"2016","unstructured":"Vickers AD, Ainsworth C, Mody R, et al. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS ONE. 2016;11:e0165435. https:\/\/doi.org\/10.1371\/journal.pone.0165435.","journal-title":"PLoS ONE"},{"key":"3003_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ecco-jcc\/jjac150","volume":"17","author":"P Bahnam","year":"2023","unstructured":"Bahnam P, Hanzel J, Ma C, et al. Most placebo-controlled trials in inflammatory bowel disease were underpowered because of overestimated drug efficacy rates: results from a systematic review of induction studies. J Crohns Colitis. 2023;17:404\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac150.","journal-title":"J Crohns Colitis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03003-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:11:36Z","timestamp":1731139896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03003-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3003"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03003-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Axel Dignass reports no conflicts of interest for the work under consideration for publication. Claire Ainsworth, Niels Dunnewind, Sonja Kroep, Nicholas Halfpenny and Emanuele Arc\u00e0 are employees of OPEN Health at the time of this study and its analysis. OPEN Health received funding from Eli Lilly and Company for the design and conduct of this study, statistical analysis and study report preparation. Susanne Hartz, Isabel Redondo and Christophe Sapin are employees and minor shareholders of Eli Lilly and Company. Sami Hoque has no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}